CRISPR Therapeutics AG (CRSP) delivered its fourth-quarter and full-year 2025 results on Friday, and the story is all about momentum. The gene-editing company is watching its flagship therapy Casgevy gain real traction in the market while advancing a pipeline that could reshape how we treat everything from cholesterol problems to autoimmune diseases.

Casgevy's Commercial Trajectory Accelerates

Let's talk numbers. Casgevy, the gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia, brought in $54 million during the fourth quarter and $116 million for the full year. That's interesting, but here's what really matters: 147 patients initiated treatment through first cell collection during 2025. That's nearly triple the number from 2024.

Think about what that means. These aren't impulse purchases. Getting started with a gene therapy involves significant medical coordination, insurance approval, and patient commitment. The fact that initiations are accelerating this quickly suggests the therapy is proving itself in the real world, not just in clinical trials.

Of those 147 patients who started the process, 64 actually received their infusions in 2025, with 30 of those happening in the fourth quarter alone. There's naturally a lag between starting treatment and getting infused, which means that pipeline of initiated patients should translate into materially higher revenue in 2026.

William Blair picked up on this dynamic, noting that "the increase to 147 first cell collections strengthens confidence that higher initiation volumes will translate into materially greater revenue in 2026."

The access picture keeps improving too. Casgevy now has reimbursement coverage for roughly 90% of eligible patients in the U.S., which removes one of the biggest practical barriers to adoption. The therapy is also reimbursed across several European and Middle Eastern markets. In January, partner Vertex Pharmaceuticals Inc. (VRTX) secured reimbursed access for sickle cell disease patients in Scotland, adding another market to the growing list.

Beyond Blood Disorders: The Cardiovascular Play

While Casgevy grabs headlines, CRISPR's in vivo liver editing programs might be the real long-term value drivers here. The company is developing therapies that edit genes directly inside the body rather than taking cells out, modifying them, and putting them back in.

CTX310 is currently in Phase 1b trials targeting lipid disorders. Early data suggest it's holding its own against some established players. William Blair analyst Sami Corwin noted that CTX310's LDL-C reductions look competitive with what Arrowhead Pharmaceuticals Inc. (ARWR) has reported with AROANG3 and Regeneron Pharmaceuticals Inc. (REGN) has achieved with Evkeeza. Even more intriguing, the triglyceride reductions might be setting a new benchmark in the space.

Corwin wrote, "We continue to see the company's in vivo cardiovascular gene editing programs as meaningful value drivers." That's analyst-speak for "this could be huge."

Then there's CTX321, a next-generation program targeting Lp(a), which is progressing through enabling studies. The company expects to provide updates in the second half of 2026. Lp(a) is a particularly nasty form of cholesterol that doesn't respond well to statins, so an effective therapy would address a real unmet need.

Broader Pipeline Developments

CRISPR isn't putting all its eggs in one basket. The company's siRNA-based candidate CTX611, developed with Sirius Therapeutics, is in Phase 2 trials for patients undergoing knee replacement surgery. The therapy could potentially have broader applications across thromboembolic diseases, which is a fancy way of saying blood clots.

Meanwhile, zugo-cel is advancing in autoimmune and oncology indications, including systemic lupus erythematosus and B-cell malignancies. The company is evaluating zugo-cel in combination with pirtobrutinib under a collaboration with Eli Lilly and Co. (LLY). Previous data showed a 90% response rate in aggressive blood cancers, which is the kind of number that makes oncologists pay attention.

Financial Position and Runway

CRISPR ended 2025 with $1.98 billion in cash and marketable securities, which provides plenty of runway for its clinical programs. R&D expenses climbed to $83.5 million in the fourth quarter, reflecting the expanding pipeline. The net loss widened to $130.6 million in the fourth quarter from $37.3 million a year earlier, which is what you'd expect as a company scales up its development efforts.

The market seemed to like what it saw. CRSP shares jumped 8.81% to $53.24 on Friday following the announcement.

The big picture here is a company transitioning from pure development to commercial execution while keeping its pipeline active. Casgevy's accelerating adoption provides validation that gene therapies can work in the real world, not just in carefully controlled trials. And if the cardiovascular programs deliver on their early promise, CRISPR could be addressing markets far larger than rare blood disorders.